IL2 and metastatic melanoma: Before 2010, only dacarbazine chemotherapy and high-dose interleukin-2 (IL-2) were approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma (Lo and Fisher, 2014).